Mestinon

Pyridostigmine bromide, the active ingredient in Mestinon, is an acetylcholinesterase inhibitor presented as a tablet for oral use. It is employed to improve muscle strength in myasthenia gravis and to alleviate orthostatic hypotension in adult patients.

GNH USA supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mestinon acts on the neuromuscular junction by increasing acetylcholine availability, benefiting conditions that involve impaired muscle activation.

- Myasthenia gravis: enhances skeletal‑muscle strength and reduces fatigue. - Orthostatic hypotension: mitigates the drop in blood pressure upon standing, improving tolerance to upright posture. - Reversal of neuromuscular blockade: shortens the duration of non‑depolarizing muscle relaxants after surgery.

Adverse reactions may occur with Mestinon use.

Common Side Effects: - Nausea - Diarrhea - Abdominal cramps - Increased salivation

Serious or Rare Side Effects: - Bradycardia - Severe bronchospasm - Allergic reactions such as rash or angioedema

Before initiating therapy, consider the following safety measures.

- Adjust dose in renal impairment: reduce dosage according to renal function. - Monitor for cholinergic crisis: watch for worsening muscle weakness or respiratory difficulty. - Caution in patients with asthma or COPD: risk of bronchospasm may be heightened. - Avoid concurrent use with anticholinergic agents: may diminish therapeutic effect. - Use with caution in pregnancy: limited data, weigh risk versus benefit. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Pyridostigmine may interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Neostigmine: additive cholinergic effects may precipitate crisis. - Beta‑blockers: can exacerbate bradycardia. - Magnesium sulfate: enhances neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Aminoglycoside antibiotics: may increase risk of neuromuscular weakness. - Succinylcholine or other depolarizing anesthetics: may prolong muscle relaxation. - Diuretics: can alter electrolyte balance affecting drug activity.